Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit
August 23 2021 - 5:00PM
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage
biopharmaceutical company on a mission to develop treatments that
restore cognitive function, today announced participation in the
Annual Biomarkers for Alzheimer’s Disease Summit taking place
virtually August 25-26, 2021. Chris Winrow, Ph.D., Head of
Translational Medicine, will present on biomarker translation and
the potential that early clinical assessment of biomarkers has to
drive development of Alzheimer’s disease therapies, and Juli Jones,
Ph.D., Head of Disease Biology, will be leading a session exploring
the utilization of omics platforms in drug discovery.
Presentation
Details:
Title: Exploring the Utilization of Omics
Platforms in Drug DiscoveryModerator: Juli
Jones Ph.D., Head of Disease Biology, Cyclerion Therapeutics,
Inc.Date: Wednesday, August 25,
2021Time: 4:20 p.m. ET
Title: Leading the Vanguard – Early
Clinical Assessment of Biomarkers to Drive Development of
Alzheimer’s Disease TherapiesPresenter: Chris
Winrow, Ph.D., Head of Translational Medicine, Cyclerion
Therapeutics, Inc.Date: Thursday, August 26,
2021Time: 2:30 p.m. ET followed by a live
Q&A at 3:00 p.m. ET
About Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical
company on a mission to develop treatments that restore cognitive
function. Cyclerion is advancing novel, first-in-class,
CNS-penetrant, sGC stimulators that modulate a key node in a
fundamental CNS signaling pathway. The multidimensional
pharmacology elicited by the stimulation of sGC has the potential
to impact a broad range of CNS diseases. The most advanced
compound, CY6463, has shown rapid improvement in biomarkers
associated with cognitive function and is currently in clinical
development for Alzheimer's Disease with Vascular pathology (ADv),
Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like
episodes (MELAS), and Cognitive Impairment Associated with
Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a
next-generation sGC stimulator.
For more information about Cyclerion, please
visit https://www.cyclerion.com/ and follow us on Twitter
(@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).
InvestorsCarlo Tanzi, Ph.D.Kendall Investor
Relationsctanzi@kendallir.com
MediaAmanda SellersVerge Scientific
Communicationsasellers@vergescientific.com
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Apr 2023 to Apr 2024